Jump to content
Sign in to follow this  

Genentech’s Alecensa Helped People With Alk-Positive

Recommended Posts

Genentech’s Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death


“Follow-up results from the ALEX study demonstrate the significant sustained benefit of Alecensa, showing that people with metastatic ALK-positive non-small cell lung cancer lived for almost three years without their disease progressing,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “These results further support the use of Alecensa as a standard of care for people who are newly diagnosed with this form of lung cancer.” https://www.gene.com/media/press-releases/14721/2018-05-16/follow-up-phase-iii-data-showed-genentec




Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this